APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Federal policy relating to the reauthorization of the Generic Drug User Fee Act; Federal policy relating to the cost of prescription pharmaceuticals; Federal policy relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; HR 749, the Lower Drug Costs Through Competition Act, provisions relating to priority review vouchers for and expedited approval of certain generic drug applications, and Risk Evaluation and Mitigation (REMS) programs; and Draft legislation (no bill number) related to generic drug exclusivity and the review of Abbreviated New Drug Applications (ANDAs).
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.